One drug approved for Brazil, 2nd one pending approval, planto launch generic Epidiolex in the U.S....all from the CC....this stock should be flying over $2 by now based strictly upon forward looking fundamentals already publicly disclosed.
It's a wonderful position to be in for those that have extra cash to buy more now, it really is.
on a side note: it wouldn't surprise me if the likes of Canopy and Tilray have already talked to LABS to do CDMO work for them. Let's cast aside the 'white label' nomenclature because LABS is a pharmaceutical company and they provide CDMO services.